Since many inhibitors share the binding region of the Sec61α subunit (Paatero et al., 2016; Zong et al., 2019; Baron et al., 2016), Sec61α shows great potential as a molecular target for the treatment of various conditions, such as cancer, immune disorders, and viral infections (Pauwels et al., 2021a). Here, SEC61A1 is linked to immune system disorder.